"Five years ago, you couldn't get a meeting with a [venture capitalist] if you said you were developing a drug for weight loss. It was a space that investors did not want to touch, given the failures and the challenges with getting drugs approved. With the success of Novo and Lily getting their drugs approved, that's obviously changed drastically."
"The class of expensive GLP-1 drugs touches on broader themes that will affect the life sciences in the coming year, such as drug pricing and regulation. Pricing and access to drugs and medical devices is the most significant issue."
"Deloitte's survey shows that pricing and access to significantly affect their strategies. 47% expect pricing and access to have a significant impact, while 49% expect a moderate impact."
Collection
[
|
...
]